SLC7A11-IN-1

• CAT Number: I041369
• Molecular Formula: C13H15Cl2F3N4O5PtS
• Molecular Weight: 662.33
• Purity: ≥95%
• Synonyms: azanide;dichloroplatinum(2+);5-oxo-5-[[6-(trifluoromethoxy)-1,3-benzothiazol-2-yl]amino]pentanoic acid;hydrate
• InChI: InChI=1S/C13H11F3N2O4S.2ClH.2H2N.H2O.Pt/c14-13(15,16)22-7-4-5-8-9(6-7)23-12(17-8)18-10(19)2-1-3-11(20)21;;;;;;/h4-6H,1-3H2,(H,20,21)(H,17,18,19);2*1H;3*1H2;/q;;;2*-1;;+4/p-2
• InChIKey: RAVPGHGJOKGQFM-UHFFFAOYSA-L
• SMILES: C1=CC2=C(C=C1OC(F)(F)F)SC(=N2)NC(=O)CCCC(=O)O.[NH2-].[NH2-].O.Cl[Pt+2]Cl

SLC7A11-IN-1 is a potent solute carrier family 7 member 11 (SLC7A11, xCT) inhibitor. SLC7A11-IN-1 shows antiproliferative activity. SLC7A11-IN-1 inhibits cell invasion and metastasis. SLC7A11-IN-1 induces Apoptosis and cell cycle arrest at S-phase. SLC7A11-IN-1 shows anti-tumor activity[1].
SLC7A11-IN-1 (compound 2; 0-100 µM; 72 h) shows antiproliferative activity with IC50s of 0.03, 0.11, 0.18, 0.17, 0.27 µM for HCT-116, MDA-MB-231, MCF-7, HepG2, LO2 cells, respectively[1].
SLC7A11-IN-1 (0.5 µM; 24 h) inhibits invasion and metastasis of HCT-116 cells[1].
SLC7A11-IN-1 (0.5 µM; 24 h) induces cell apoptosis and cell cycle arrest at S-phase[1].
SLC7A11-IN-1 obviously reduces the intracellular GSH content and significantly enhances reactive oxygen species (ROS) expression[1].
SLC7A11-IN-1 (1 µM; 15 h) significantly induced DNA damage and related proteins expression in HCT-116 cells[1].
SLC7A11-IN-1 (2 mg/kg; i.v.; every three days for consecutive 3 times) inhibits the growth of tumors in mice[1].

Reference

[1]. Li Z, et al. Blocking xCT and PI3K/Akt pathway synergized with DNA damage of Riluzole-Pt(IV) prodrugs for cancer treatment. Eur J Med Chem. 2023 Mar 15;250:115233.
 [Content Brief]